Former President Donald Trump and Vice President Kamala Harris have a rare point of agreement in their otherwise bitter and divisive contest: It's up to the government to cut high U.S. drug prices.

Viking Therapeutics' dual-action contender could add to pharmacy benefits cost pressure.

Rep. Nick Langworthy asked about duty of care at a committee hearing featuring three top PBM executives.

It is important to remember that when medication adherence fell as a result of the introduction of an HSA-eligible health plan.